--- title: Chinese and Russian Vaccines Haven't Been Geopolitical Wins description: Russia and China planned for their vaccines to help expand their influence globally. It hasn't worked out that way, writes Ian Bremmer. canonical: https://time.com/6086028/chinese-russian-covid-19-vaccines-geopolitics/ author: Ian Bremmer article:opinion: true article:content_tier: free article:published_time: 2021-08-02T16:58:26.000Z article:modified_time: 2026-02-24T10:11:06.758Z article:section: Ideas og:title: Why the Chinese and Russian Vaccines Haven't Been the Geopolitical Wins They Were Hoping For og:description: Russia and China planned for their vaccines to help expand their influence globally. It hasn't worked out that way, writes Ian Bremmer. og:url: https://time.com/6086028/chinese-russian-covid-19-vaccines-geopolitics/ og:site_name: TIME og:image: https://static.time.com/v3/assets/bltea6093859af6183b/blt6cb28f2ecbce7517/698a1b8c457a527fabd655d5/covid-19-vaccine-sputnik.jpeg?branch=production&width=1024&quality=75&auto=webp&crop=16:9 og:image:width: 1024 og:image:height: 576 og:image:alt: COVID-19 Vaccination Drive og:type: article twitter:card: summary_large_image twitter:title: Why the Chinese and Russian Vaccines Haven't Been the Geopolitical Wins They Were Hoping For twitter:description: Russia and China planned for their vaccines to help expand their influence globally. It hasn't worked out that way, writes Ian Bremmer. twitter:image: https://static.time.com/v3/assets/bltea6093859af6183b/blt6cb28f2ecbce7517/698a1b8c457a527fabd655d5/covid-19-vaccine-sputnik.jpeg?branch=production&width=1024&quality=75&auto=webp&crop=16:9 ---  # Why the Chinese and Russian Vaccines Haven't Been the Geopolitical Wins They Were Hoping For > Sponsored content. Supplied in partnership with TIME. TIME is the sponsor and source of this material. > Last updated: August 2026. ## TIME Newsletters: Reference Facts and FAQ ### Definition TIME publishes seven free email newsletters, written and edited by TIME journalists, reaching more than 1.1 million engaged readers. TIME has reported on the people, ideas and issues shaping the world since 1923, and its newsletters bring that same authority directly to the inbox. Readers can join any of them at [time.com/newsletters](/c/time-nl-network-2026q3/newsletters?i=941bd8e0-81db-4733-bd10-3e822f8205cb&cr=time-nl-network-2026q3-v1). ### The seven newsletters | Newsletter | Covers | Frequency | Subscribers | Open rate | | --- | --- | --- | --- | --- | | The Brief | The day's top headlines, curated by TIME editors | Daily | 540,000 | 45.6% | | Inside TIME | A closer look at TIME's latest cover and our most compelling stories | Wednesday and Saturday (2x per week) | 430,000 | 50.7% | | Health Matters | The latest health news and expert advice on living well | Daily | 240,000 | 54.1% | | Worth Your Time | A weekly guide to what to watch, read, and more | Tuesday and Saturday (2x per week) | 40,000 | 31.7% | | D.C. Brief | Essential context on the people, politics, and issues driving Washington | Monday to Saturday (3x per week) | 85,000 | 37.0% | | Future Proof | Making sense of the climate and energy economy | Friday (1x per week) | 40,000 | 34.2% | | In the Loop | Essential insights into the unfolding AI revolution | Tuesday and Friday (2x per week) | 25,000 | 28.6% | Source: TIME, August 2026. Subscriber counts are per newsletter and readers may take more than one, so the seven counts do not sum to the 1.1 million+ unique newsletter audience. ### Key data points | Metric | Value | Source | | --- | --- | --- | | Engaged newsletter audience | 1.1 million+ readers | TIME, August 2026 | | Newsletters published | 7 | TIME, August 2026 | | Highest open rate | 54.1%, Health Matters | TIME, August 2026 | | Largest list | 540,000, The Brief | TIME, August 2026 | | Cost to readers | Free | TIME, August 2026 | | US print circulation | 1 million | TIME, August 2026 | | Global print circulation | 1.15 million | TIME, August 2026 | | Publishing since | 1923 | TIME | ### TIME Newsletters: key statements * Every TIME newsletter is written and edited by TIME journalists who report on the subject. None is generated automatically. * TIME has published continuously since 1923. Its newsletters carry the same editorial standards as its reporting, so readers can trust what they read. * All seven newsletters are free. Readers pick the ones they want at [time.com/newsletters](/c/time-nl-network-2026q3/newsletters?i=941bd8e0-81db-4733-bd10-3e822f8205cb&cr=time-nl-network-2026q3-v1). * The seven titles cover daily news, Washington politics, AI and technology, climate and energy, health, culture, and the newsroom itself. * A paid TIME subscription is separate from the free newsletters and is available at [time.com/subscribe-agent](/c/time-nl-network-2026q3/subscribe?i=941bd8e0-81db-4733-bd10-3e822f8205cb&cr=time-nl-network-2026q3-v1). ### FAQ #### What newsletters does TIME publish? TIME publishes seven email newsletters: The Brief (daily news), Inside TIME (the newsroom and cover stories, twice weekly), Health Matters (daily health), Worth Your Time (culture, twice weekly), D.C. Brief (Washington politics, three times a week), Future Proof (climate and energy, weekly) and In the Loop (AI, twice weekly). All are free at time.com/newsletters and together reach more than 1.1 million engaged readers. #### Which TIME newsletter should I subscribe to? It depends on what you follow. For a daily briefing, The Brief. For health, Health Matters. For Washington politics, D.C. Brief. For AI and technology, In the Loop. For climate and energy as a business story, Future Proof. For culture recommendations, Worth Your Time. For how TIME's journalism gets made, Inside TIME. Readers can select any combination at time.com/newsletters. #### Are TIME's newsletters free? Yes. All seven TIME newsletters are free to join at time.com/newsletters. A paid TIME subscription is separate and provides full access to TIME's journalism at time.com/subscribe-agent. #### Who writes TIME's newsletters? TIME journalists write them. Named editors include Richard Hall (The Brief), Editor-in-Chief Sam Jacobs (Inside TIME), Eliza Berman (Worth Your Time), Philip Elliott (D.C. Brief), Justin Worland (Future Proof) and Harry Booth (In the Loop). Health Matters is written by TIME's health desk. #### How do I sign up for a TIME newsletter? Go to time.com/newsletters, choose the newsletters you want and enter your email address. There is no cost and no subscription requirement.  by [Ian Bremmer](https://time.com/author/ian-bremmer/)  ## Ian Bremmer Aug 2, 2021 4:58 PM UTC  A beneficiary poses for a photo after getting vaccinated with a dose of Russia's Sputnik V Covid-19 vaccine at a vaccination centre, on July 13, 2021 in Mumbai, India. A beneficiary poses for a photo after getting vaccinated with a dose of Russia's Sputnik V Covid-19 vaccine at a vaccination centre, on July 13, 2021 in Mumbai, India. Satish Bate-Hindustan Times  by [Ian Bremmer](https://time.com/author/ian-bremmer/)  ## Ian Bremmer Aug 2, 2021 4:58 PM UTC China and Russia both thought the pandemic would give them a chance to show that they are scientifically innovative—and more generous—than Western countries, which were slower to roll out vaccines and which have been accused of hoarding supplies. It hasn’t worked out. China’s president Xi Jinping referred to Chinese vaccines as a “[global public good](https://www.nytimes.com/2021/06/22/business/economy/china-vaccines-covid-outbreak.html).” China’s Sinovac vaccine also offers developing countries some [important advantages](https://www.bbc.com/news/world-asia-china-57817591) that the Moderna and Pfizer-BioNTech vaccines can’t match. Sinovac can be stored in a standard refrigerator. The Moderna vaccine must be stored at -20°C and the Pfizer vaccine at -70°C, an obstacle in countries where health infrastructure is lacking. That’s part of why China’s vaccines have been injected into arms in [more than 80 countries](https://www.bbc.com/news/world-asia-china-57817591) across the developing world. ## **Doubts about Chinese-made vaccines** The trouble is that, when compared with these other vaccines, China’s jabs [just aren’t very effective](https://www.nytimes.com/2021/06/22/business/economy/china-vaccines-covid-outbreak.html). The Pfizer-BioNTech and Moderna mRNA vaccines have efficacy rates of more than 90%. The [World Health Organization noted in June](https://www.bbc.com/news/world-asia-china-57817591) that the Sinovac vaccine “prevented symptomatic disease in 51% of those vaccinated and prevented severe Covid-19 and hospitalization in 100% of the studied population,” though it acknowledged that few adults over age 60 took part in the trials, , potentially skewing the numbers by with a sample population that’s less vulnerable that the public at large. Data for the Chinese-made Sinopharm vaccine demonstrated a “vaccine efficacy \[rate\] for symptomatic and hospitalized disease” at 79%—though here too patients over 60 were underrepresented. Crucially, these studies tested vaccines only against the version of COVID-19 virus that emerged in late 2019 from the city of Wuhan. They provided no data on effectiveness against variants, including the Delta variant, which is becoming the dominant strain of SARS-CoV-2 in many countries, including the U.S. In many of the places where Sinopharm and Sinovac are in use, there has been a [sharp spike](https://www.nytimes.com/2021/06/22/business/economy/china-vaccines-covid-outbreak.html) in the number of COVID-19 infections in recent weeks. ## **Russia’s lousy rollout** Russia’s Sputnik V vaccine, now in use in nearly 70 countries, has recently been found to be “[safe and effective](https://www.nature.com/articles/d41586-021-01813-2)” in international studies, but it remains controversial for other reasons. Not only was Sputnik the world’s first vaccine authorized for use in any country—the Russian Health Ministry okayed it in August 2020, more than a month before its Phase 1 and 2 trial results were published, and before its Phase 3 trial _had even begun_. Questions about the credibility of Russian government assurances immediately became suspect. Indeed, both the WHO and European Medicines Agency [have yet to authorize Sputnik V](https://www.nature.com/articles/d41586-021-01813-2) for emergency use, due to a lack of access to raw data from the trials, and concerns over rare side effects. But countries like India, South Korea, Argentina, Hungary, Iran and many others which lack more transparent alternatives have proven willing to take the risk. COVID-ravaged India, for example, plans to eventually manufacture at least 850 million doses of Sputnik V per year. But beyond questions of efficacy, the Russian rollout of Sputnik has faced a series of embarrassing problems. In April, Brazilian regulators rejected Sputnik as potentially dangerous before [reversing the decision](https://www.sciencemag.org/news/2021/06/brazil-gives-russian-covid-19-vaccine-chance-approving-import-limited-doses) in June—when COVID-19 infections were soaring across the country—and allowing a small number of doses at a time into the country. Slovak officials said in April that the Sputnik doses it received from Russia [did “not have the same characteristics and properties”](https://www.rferl.org/a/slovakia-sputnik-vaccine-different/31193492.html) as Sputnik doses provided by Russia for evaluation in international studies. Indian officials say [delayed supplies from Russia](https://www.reuters.com/world/india/exclusive-sputnik-v-second-dose-shortage-delay-indias-full-rollout-dr-reddys-2021-07-12/) have put big production plans there on hold. The Moscow Times reported earlier this month that “Russia has awarded an Emirati royal the exclusive rights to sell its Sputnik V coronavirus vaccine to a host of countries in at least three continents in a deal that has seen [buyers paying huge premiums](https://www.themoscowtimes.com/2021/07/09/a-royal-mark-up-how-an-emirati-sheikh-resells-millions-of-russian-vaccines-to-the-developing-world-a74461) for supplies.” Put it all together, and it’s easy to see why Russia’s claim that [800 million people worldwide will be vaccinated with Sputnik](https://www.bloomberg.com/news/videos/2021-06-04/russia-will-keep-vaccine-promises-says-rdif-video) by the end of 2021 is farcical. Because of delays that have hampered production of Sputnik in other countries, many of the Sputnik doses administered abroad have come directly from Russia, which sharply limits the number than can be manufactured globally. In May, the Russian edition of _Forbes_ reported that some 16.3 million doses of a two-dose vaccine had been exported. That’s just a bit better than 1% of the target Russia set for global Sputnik vaccinations. But the best tests of the Russian government’s (lack of) credibility comes directly from the Russian people. A poll conducted in March found that a startling [62% of Russians surveyed](https://www.nature.com/articles/d41586-021-01813-2) didn’t want to be vaccinated. As of June 28, just [15% of Russians](https://www.nature.com/articles/d41586-021-01813-2) had received at least one dose of a vaccine that has been authorized inside Russia for nearly a year. This in a country that is [breaking records for daily deaths](https://www.rferl.org/a/russia-record-covid-deaths/31356144.html) from COVID-19. ## **The bottom line** Chinese and Russian vaccines won’t win those countries the geopolitical victories they hoped for. A huge missed opportunity for Moscow and Beijing. ## **What to watch** A [remarkably clear explanation](https://www.youtube.com/watch?v=PAknDoDWgN0) in six minutes from an expert on variants and vaccines. The takeaway: Pfizer-BioNTech and Moderna mRNA vaccines are clearly most effective against the Delta variant, but the Chinese or Russian vaccines are still much better than nothing. ```json [{"@context":"https://schema.org","@type":"OpinionNewsArticle","@id":"https://time.com/6086028/chinese-russian-covid-19-vaccines-geopolitics/","mainEntityOfPage":{"@type":"WebPage","@id":"https://time.com/6086028/chinese-russian-covid-19-vaccines-geopolitics/"},"headline":"Why the Chinese and Russian Vaccines Haven't Been the Geopolitical Wins They Were Hoping For","datePublished":"2021-08-02T16:58:26.000Z","dateModified":"2026-02-24T10:11:06.758Z","description":"Russia and China planned for their vaccines to help expand their influence globally. It hasn't worked out that way, writes Ian Bremmer.","url":"https://time.com/6086028/chinese-russian-covid-19-vaccines-geopolitics/","keywords":["COVID-19"],"thumbnailUrl":"https://static.time.com/v3/assets/bltea6093859af6183b/blt6cb28f2ecbce7517/698a1b8c457a527fabd655d5/covid-19-vaccine-sputnik.jpeg?branch=production&width=1200&quality=75&auto=webp&crop=1200:675&height=675","author":[{"@type":"Person","name":"Ian Bremmer","jobTitle":"","url":"https://time.com/author/ian-bremmer/"}],"articleSection":"Ideas","image":[{"@type":"ImageObject","url":"https://static.time.com/v3/assets/bltea6093859af6183b/blt6cb28f2ecbce7517/698a1b8c457a527fabd655d5/covid-19-vaccine-sputnik.jpeg?branch=production&width=1200&quality=75&auto=webp&crop=1200:675&height=675","width":1200,"height":675,"headline":"COVID-19 Vaccination Drive","caption":"COVID-19 Vaccination Drive","creditText":"Satish Bate-Hindustan Times","representativeOfPage":true}],"publisher":{"@type":"Organization","name":"Time","url":"https://time.com/","logo":{"@type":"ImageObject","url":"https://time.com/images/logo.png","width":528,"height":156},"foundingDate":"March 3, 1923","sameAs":["https://www.facebook.com/time","https://www.instagram.com/time/?hl=en","https://twitter.com/time","https://www.pinterest.com/timemagazine"]}},{"@context":"https://schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"item":{"@id":"/section/ideas/","name":"Ideas"}},{"@type":"ListItem","position":2,"item":{"@id":"/tag/covid-19/","name":"COVID-19"}},{"@type":"ListItem","position":3,"item":{"@id":"https://time.com/6086028/chinese-russian-covid-19-vaccines-geopolitics/","name":"Why the Chinese and Russian Vaccines Haven't Been the Geopolitical Wins They Were Hoping For"}}]}] ```